The future of vaccines for cervical cancer

Gynecologic Oncology

Volumn 109, Issue 2 SUPPL., 2008, Pages

  Huh, Warner K ^a   Roden, Richard B S ^b,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cervical cancer; HPV; Vaccine; VLP

Indexed keywords

ADENOVIRUS VECTOR; ALUMINUM HYDROXIDE; HEAT SHOCK PROTEIN 70; PHOSPHORYL LIPID A; PROTEIN E6; PROTEIN E7; TRANSCRIPTION FACTOR E2A; VACCINIA VACCINE; WART VIRUS VACCINE;

ANTIBODY RESPONSE; CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; INCIDENCE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; UTERINE CERVIX CANCER; VACCINATION; VIRUS LOAD; VIRUS STRAIN; WART VIRUS;

ALPHAPAPILLOMAVIRUS; CANCER VACCINES; CAPSID PROTEINS; FEMALE; FORECASTING; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 43049160856     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.01.004     Document Type: Review

References (85)

1. Dunne E.F., Unger E.R., Sternberg M., McQuillan G., Swan D.C., Patel S.S., et al. Prevalence of HPV infection among females in the United States. JAMA 297 8 (Feb 28 2007) 813-819
2. Centers for Disease Control. Genital HPV - CDC Fact Sheet. Available at: http://www.cdc.gov/std/HPV/STDFact-HPV.htm.
3. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121 3 (Aug 1 2007) 621-632
4. Saslow D., Castle P.E., Cox J.T., Davey D.D., Einstein M.H., Ferris D.G., et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 57 1 (Jan-Feb 2007) 7-28
5. Burd E.M. Human papillomavirus and cervical cancer. Clin Microbiol Rev 16 1 (Jan 2003) 1-17
6. Syrjanen S.M., and Syrjanen K.J. New concepts on the role of human papillomavirus in cell cycle regulation. Ann Med 31 3 (Jun 1999) 175-187
7. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 9518 (Apr 15 2006) 1247-1255
8. Bryan J.T. Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine 25 16 (Apr 20 2007) 3001-3006
9. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24 33-34 (Aug 14 2006) 5937-5949
10. Stanley M., Lowy D.R., and Frazer I. Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine 24 Suppl 3 (Aug 21 2006) S106-S113
11. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 92 25 (Dec 5 1995) 11553-11557
12. Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69 6 (Jun 1995) 3959-3963
13. FUTURE, II. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 19 (May 10 2007) 1915-1927
14. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 9580 (Jun 30 2007) 2161-2170
15. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 24 27-28 (Jul 7 2006) 5571-5583
16. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 5 (May 2005) 271-278
17. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 11 (Dec 4 2006) 1459-1466
18. Gall S., Teixeira J., Wheeler C., Naud P., Harper D.M., Franco E.L., Quint W., Zahaf T., Schuind A., Jenkins D., Dubin G., and on behalf of the HPV Vaccine Study Group. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine. Proceedings of the AACR Annual Meeting (2007). http://www.aacr.org/home/scientists/meetings-workshops/annual-meeting-2007/publications.aspx Available at: http://www.aacr.org/home/scientists/meetings-workshops/annual-meeting-2007/publications.aspx
19. Brown D. HPV type 6/11/16/18 vaccine: First analysis of cross-protection against persistent infection, cervical intraepithelial neoplasia (CIN), and adenocarcinoma in situ (AIS) caused by oncogenic HPV types in addition to 16/18. Poster presentation at the 47th interscience conference on antimicrobial agents and chemotherapy (September 17-20 2007), Chicago, IL
20. Kreimer A.R., Clifford G.M., Boyle P., and Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14 2 (Feb 2005) 467-475
21. Varnai A.D., Bollmann M., Griefingholt H., Speich N., Schmitt C., Bollmann R., et al. HPV in anal squamous cell carcinoma and anal intraepithelial neoplasia (AIN). Impact of HPV analysis of anal lesions on diagnosis and prognosis. Int J Colorectal Dis 21 2 (Mar 2006) 135-142
22. Ferenczy A., and Franco E.L. Prophylactic human papillomavirus vaccines: potential for sea change. Expert Rev Vaccines 6 4 (Aug 2007) 511-525
23. Slupetzky K., Gambhira R., Culp T.D., Shafti-Keramat S., Schellenbacher C., Christensen N.D., et al. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 25 11 (Mar 1 2007) 2001-2010
24. Xu Y., Wang Q., Han Y., Song G., and Xu X. Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles. J Med Microbiol 56 Pt 7 (Jul 2007) 907-913
25. Hildesheim A., Herrero R., Wacholder S., Rodriguez A.C., Solomon D., Bratti M.C., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298 7 (Aug 15 2007) 743-753
26. Brinkman J.A., Caffrey A.S., Muderspach L.I., Roman L.D., and Kast W.M. The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management. Eur J Gynaecol Oncol 26 2 (2005) 129-142
27. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55 4 (Apr 2002) 244-265
28. Wentzensen N., Vinokurova S., and von Knebel Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 64 11 (Jun 1 2004) 3878-3884
29. Kobayashi A., Greenblatt R.M., Anastos K., Minkoff H., Massad L.S., Young M., et al. Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 64 18 (Sep 15 2004) 6766-6774
30. Busnach G., Piselli P., Arbustini E., Baccarani U., Burra P., Carrieri M.P., et al. Immunosuppression and cancer: A comparison of risks in recipients of organ transplants and in HIV-positive individuals. Transplant Proc 38 10 (Dec 2006) 3533-3535
31. Kadish A.S., Timmins P., Wang Y., Ho G.Y., Burk R.D., Ketz J., et al. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev 11 5 (May 2002) 483-488
32. Nakagawa M., Stites D.P., Farhat S., Judd A., Moscicki A.B., Canchola A.J., et al. T-cell proliferative response to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia. Clin Diagn Lab Immunol 3 2 (Mar 1996) 205-210
33. Tigris Pharmaceuticals I. Research and Development 2007. Available at: http://www.tigrispharma.com/a007.html.
34. Zwaveling S., Ferreira Mota S.C., Nouta J., Johnson M., Lipford G.B., Offringa R., et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 169 1 (Jul 1 2002) 350-358
35. Steller M.A., Gurski K.J., Murakami M., Daniel R.W., Shah K.V., Celis E., et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 4 9 (Sep 1998) 2103-2109
36. Muderspach L., Wilczynski S., Roman L., Bade L., Felix J., Small L.A., et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6 9 (Sep 2000) 3406-3416
37. Melief C.J.M. Immunotherapy of established papilloma virus-induced (pre-) malignant lesions in mice, rabbits and patients. Ann Oncol 17 3 (2006) iii28
38. Qian X., Lu Y., Liu Q., Chen K., Zhao Q., and Song J. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model. Immunol Lett 102 2 (Feb 15 2006) 191-201
39. Einstein M.H., Kadish A.S., Burk R.D., Kim M.Y., Wadler S., Streicher H., et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 106 3 (Sep 2007) 453-460
40. ClinicalTrails.gov. Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia. Available at: http://www.clinicaltrials.gov/ct/show/NCT00493545?order=11.
41. Santin A.D., Bellone S., Palmieri M., Ravaggi A., Romani C., Tassi R., et al. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol 100 3 (Mar 2006) 469-478
42. Clinical Trails.gov. Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs). Available at: http://www.clinicaltrials.gov/ct/show/NCT00155766?order=2.
43. Qian J., Dong Y., Pang Y.Y., Ibrahim R., Berzofsky J.A., Schiller J.T., et al. Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. Int J Cancer 118 12 (Jun 15 2006) 3022-3029
44. Kaufmann A.M., Nieland J.D., Jochmus I., Baur S., Friese K., Gabelsberger J., et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 121 12 (Dec 15 2007) 2794-2800
45. de Jong A., O'Neill T., Khan A.Y., Kwappenberg K.M., Chisholm S.E., Whittle N.R., et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 20 29-30 (Oct 4 2002) 3456-3464
46. Gambhira R., Gravitt P.E., Bossis I., Stern P.L., Viscidi R.P., and Roden R.B. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res 66 23 (Dec 1 2006) 11120-11124
47. Fiander A.N., Tristram A.J., Davidson E.J., Tomlinson A.E., Man S., Baldwin P.J., et al. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer 16 3 (May-Jun 2006) 1075-1081
48. Davidson E.J., Faulkner R.L., Sehr P., Pawlita M., Smyth L.J., Burt D.J., et al. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine 22 21-22 (Jul 29 2004) 2722-2729
49. Smyth L.J., Van Poelgeest M.I., Davidson E.J., Kwappenberg K.M., Burt D., Sehr P., et al. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res 10 9 (May 1 2004) 2954-2961
50. Ohlschlager P., Pes M., Osen W., Durst M., Schneider A., Gissmann L., et al. An improved rearranged human papillomavirus type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine 24 15 (Apr 5 2006) 2880-2893
51. Brulet J.M., Maudoux F., Thomas S., Thielemans K., Burny A., Leo O., et al. DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection. Eur J Immunol 37 2 (Feb 2007) 376-384
52. Kang T.H., Lee J.H., Bae H.C., Noh K.H., Kim J.H., Song C.K., et al. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments. Immunol Lett 106 2 (Aug 15 2006) 126-134
53. Hung C.F., Tsai Y.C., He L., and Wu T.C. DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. Mol Ther 15 6 (Jun 2007) 1211-1219
54. Peng S., Tomson T.T., Trimble C., He L., Hung C.F., and Wu T.C. A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther 13 3 (Feb 2006) 257-265
55. Hung C.F., Yang M., and Wu T.C. Modifying professional antigen-presenting cells to enhance DNA vaccine potency. Methods Mol Med 127 (2006) 199-220
56. Hsieh C.Y., Chen C.A., Huang C.Y., Chang M.C., Lee C.N., Su Y.N., et al. IL-6-encoding tumor antigen generates potent cancer immunotherapy through antigen processing and anti-apoptotic pathways. Mol Ther 15 10 (Oct 2007) 1890-1897
57. Brinkman J.A., Xu X., and Kast W.M. The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors. Vaccine 25 17 (Apr 30 2007) 3437-3444
58. Gasparic M., Rubio I., Thones N., Gissmann L., and Muller M. Prophylactic DNA immunization against multiple papillomavirus types. Vaccine 25 23 (Jun 6 2007) 4540-4553
59. ClinicalTrials.gov. Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia. Available at: http://www.clinicaltrials.gov/ct/show/NCT00121173?order=4.
60. Kaufmann A.M., Stern P.L., Rankin E.M., Sommer H., Nuessler V., Schneider A., et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 8 12 (Dec 2002) 3676-3685
61. Transgene. Sustained Response at Month 12 for Transgene's TG 4001 in HPV-induced Precancerous Lesions of the Cervix and Next Clinical Development Steps 2006:3.
62. Corona Gutierrez C.M., Tinoco A., Navarro T., Contreras M.L., Cortes R.R., Calzado P., et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 15 5 (May 2004) 421-431
63. Garcia-Hernandez E., Gonzalez-Sanchez J.L., Andrade-Manzano A., Contreras M.L., Padilla S., Guzman C.C., et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 13 6 (Jun 2006) 592-597
64. Kim D., Elizaga M., and Duerr A. HIV vaccine efficacy trials: towards the future of HIV prevention. Infect Dis Clin North Am 21 1 (Mar 2007) 201-217 x
65. Jin H.S., Park E.K., Lee J.M., NamKoong S.E., Kim D.G., Lee Y.J., et al. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor. Gynecol Oncol 97 2 (May 2005) 559-567
66. Baez-Astua A., Herraez-Hernandez E., Garbi N., Pasolli H.A., Juarez V., Zur Hausen H., et al. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses. J Virol 79 20 (Oct 2005) 12807-12817
67. Gomez-Gutierrez J.G., Elpek K.G., Montes de Oca-Luna R., Shirwan H., Sam Zhou H., and McMasters K.M. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother 56 7 (Jul 2007) 997-1007
68. Berg M., Gambhira R., Siracusa M., Hoiczyk E., Roden R., and Ketner G. HPV16 L1 capsid protein expressed from viable adenovirus recombinants elicits neutralizing antibody in mice. Vaccine 25 17 (Apr 30 2007) 3501-3510
69. Fraser C., Tomassini J.E., Xi L., Golm G., Watson M., Giuliano A.R., et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 25 21 (May 22 2007) 4324-4333
70. Viscidi R.P., Schiffman M., Hildesheim A., Herrero R., Castle P.E., Bratti M.C., et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 13 2 (Feb 2004) 324-327
71. Lehtinen M., Herrero R., Mayaud P., Barnabas R., Dillner J., Paavonen J., et al. Chapter 28: studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 24 Suppl 3 (Aug 21 2006) S233-S241
72. Luna J., Saah A., Hood S., Bautista O., and Barr E. Safety, efficacy, and immunogenicity of quadrivalent HPV vaccine (Gardasil) in women aged 24-45. 24th International Papillomavirus Congress 2007 November 3-9 (2007), Beijing, China
73. Schwarz T., Dubin G., and the HPV vaccine Study Investigators for Adult Women. Human papillomavirus (HPV) 16/18 I1 AS04 virus-like particle (VLP) cervical cancer vaccine is immunogenic and well tolerated 18 months after vaccination in women up to age 55 years. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I vol. 25(18S) (2007) 3007
74. ® in Healthy Females 18-45 Years of Age. Available at: http://www.clinicaltrials.gov/ct/show/NCT00423046?order=1.
75. Giuliano A. Human papillomavirus vaccination in males. Gynecol Oncol 107 (2007) S24-S26
76. Kim J.J., Andres-Beck B., and Goldie S.J. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 97 9 (Nov 5 2007) 1322-1328
77. Palefsky J.M., Holly E.A., Ralston M.L., and Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 177 2 (Feb 1998) 361-367
78. Palefsky J.M., Holly E.A., Ralston M.L., Arthur S.P., Jay N., Berry J.M., et al. Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol 17 4 (Apr 1 1998) 320-326
79. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA: Cancer J Clin 55(2) (Mar-Apr 2005) 74-108
80. Maclean J., Koekemoer M., Olivier A.J., Stewart D., Hitzeroth II, Rademacher T., et al. Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J Gen Virol 88 Pt 5 (May 2007) 1460-1469
81. Franconi R., Massa S., Illiano E., Mullar A., Cirilli A., Accardi L., et al. Exploiting the plant secretory pathway to improve the anticancer activity of a plant-derived HPV16 E7 vaccine. Int J Immunopathol Pharmacol 19 1 (Jan-Mar 2006) 187-197
82. Aires K.A., Cianciarullo A.M., Carneiro S.M., Villa L.L., Boccardo E., Perez-Martinez G., et al. Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells. Appl Environ Microbiol 72 1 (Jan 2006) 745-752
83. Cortes-Perez N.G., Azevedo V., Alcocer-Gonzalez J.M., Rodriguez-Padilla C., Tamez-Guerra R.S., Corthier G., et al. Cell-surface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli. J Drug Target 13 2 (Feb 2005) 89-98
84. Massa S., Franconi R., Brandi R., Muller A., Mett V., Yusibov V., et al. Anti-cancer activity of plant-produced HPV16 E7 vaccine. Vaccine 25 16 (Apr 20 2007) 3018-3021
85. Bermudez-Humaran L.G., Cortes-Perez N.G., Lefevre F., Guimaraes V., Rabot S., Alcocer-Gonzalez J.M., et al. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 175 11 (Dec 1 2005) 7297-7302